SCM
Suvretta Capital Management Portfolio holdings
AUM
$2.65B
This Quarter Return
+11.78%
1 Year Return
+18.59%
3 Year Return
+180.23%
5 Year Return
+278.12%
10 Year Return
+1,101.07%
AUM
$2.79B
AUM Growth
+$2.79B
(+14%)
Cap. Flow
+$64.9M
Cap. Flow
% of AUM
2.33%
Top 10 Holdings %
Top 10 Hldgs %
40.95%
Holding
113
New
14
Increased
21
Reduced
19
Closed
15
Top Buys
| 1 |
Benitec Biopharma
BNTC
|
$65.6M |
| 2 |
Starbucks
SBUX
|
$53.6M |
| 3 |
Capital One
COF
|
$35.3M |
| 4 |
CrowdStrike
CRWD
|
$34.3M |
| 5 |
BIOA
BioAge Labs, Inc. Common Stock
BIOA
|
$30.3M |
Top Sells
| 1 |
Arcellx
ACLX
|
$69M |
| 2 |
Insmed
INSM
|
$64.7M |
| 3 |
Ultragenyx Pharmaceutical
RARE
|
$50.6M |
| 4 |
Elevance Health
ELV
|
$49.5M |
| 5 |
Sysco
SYY
|
$37.2M |
Sector Composition
| 1 | Healthcare | 59.5% |
| 2 | Technology | 11.2% |
| 3 | Consumer Discretionary | 8.56% |
| 4 | Communication Services | 7.2% |
| 5 | Financials | 5.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Biohaven
BHVN
$1.63B
| $260M | 8.31% | 5,199,219 | – | – |
|
2
Kura Oncology
KURA
$686M
| $150M | 4.78% | 7,652,782 +583,155 | +8% | +$11.4M |
|
|
3
Insmed
INSM
$28.8B
| $119M | 3.82% | 1,635,709 -886,091 | -35% | -$64.7M |
|
|
ITCI
4
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $105M | 3.37% | 1,439,026 -126,970 | -8% | -$9.29M |
|
5
Arcutis Biotherapeutics
ARQT
$1.86B
| $99.7M | 3.19% | 10,721,511 +717,019 | +7% | +$6.67M |
|
6
Meta Platforms (Facebook)
META
$1.86T
| $96.4M | 3.09% | 168,488 +1,319 | +0.8% | +$755K |
|
7
UnitedHealth
UNH
$281B
| $85.9M | 2.75% | 146,845 -14,623 | -9% | -$8.55M |
|
|
8
Benitec Biopharma
BNTC
$348M
| $81.1M | 2.6% | 8,829,053 +7,137,763 | +422% | +$65.6M |
|
9
Apple
AAPL
$3.45T
| $78.3M | 2.51% | 336,147 -27,210 | -7% | -$6.34M |
|
10
Amazon
AMZN
$2.44T
| $65.6M | 2.1% | 352,069 -4,199 | -1% | -$782K |
|
|
11
Ultragenyx Pharmaceutical
RARE
$2.89B
| $64M | 2.05% | 1,151,314 -910,112 | -44% | -$50.6M |
|
12
TSMC
TSM
$1.2T
| $60.6M | 1.94% | 348,742 -2,010 | -0.6% | -$349K |
|
13
89bio
ETNB
$1.34B
| $59.1M | 1.89% | 7,991,644 -40,201 | -0.5% | -$297K |
|
14
Apollo Global Management
APO
$77.9B
| $58.1M | 1.86% | 465,050 +110,564 | +31% | +$13.8M |
|
|
15
Arcellx
ACLX
$3.85B
| $57.6M | 1.84% | 689,950 -826,304 | -54% | -$69M |
|
16
Advanced Micro Devices
AMD
$264B
| $56.9M | 1.82% | 346,575 +577 | +0.2% | +$94.7K |
|
|
17
Starbucks
SBUX
$100B
| $53.6M | 1.72% | +550,309 | New | +$53.6M |
|
18
Goldman Sachs
GS
$226B
| $53.6M | 1.72% | 108,308 +30,360 | +39% | +$15M |
|
19
Royalty Pharma
RPRX
$15.6B
| $52.8M | 1.69% | 1,866,361 | – | – |
|
20
Tesla
TSLA
$1.08T
| $50.7M | 1.62% | 193,842 +58,929 | +44% | +$15.4M |
|
21
AT&T
T
$209B
| $50.3M | 1.61% | 2,285,336 +98,450 | +5% | +$2.17M |
|
22
CRH
CRH
$75.9B
| $50M | 1.6% | 538,894 +106,910 | +25% | +$9.91M |
|
23
KalVista Pharmaceuticals
KALV
$678M
| $48.8M | 1.56% | 4,212,005 +20,000 | +0.5% | +$232K |
|
24
Ferguson
FERG
$46.4B
| $44.7M | 1.43% | 225,210 +80,170 | +55% | +$15.9M |
|
25
ArriVent BioPharma
AVBP
$776M
| $43.4M | 1.39% | 1,845,162 +132,459 | +8% | +$3.11M |
|